title: Feprazone in osteoarthritis: comparison of twice and 3-times daily dosage regimens.
abstract: In a double-blind crossover trial, 200 mg feprazone 3-times a day was compared with 200 mg twice a day in the treatment of osteoarthritis. There was no difference in clinical efficacy or in adverse effects between the two dosage schedules. Because of its long elimination half-life (approximately 24 hours) it is suggested that feprazone should be given in twice daily dosage and is a simple and effective treatment for osteoarthritis.
mesh_terms: D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D011298:Feprazone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D010003:Osteoarthritis / Q000175:diagnosis / Q000188:drug therapy*; D010653:Phenylbutazone / Q000031:analogs & derivatives*
chemical_list: D011298:Feprazone; D010653:Phenylbutazone